Ulcerative Proctitis (Investigational Adjunct)
Highly investigational adjunct for distal ulcerative proctitis; no clinical study found; topical 5-ASA and corticosteroids remain primary.
Patient Summary
- Is this FDA-cleared for this use?
- Not FDA-cleared for ulcerative proctitis. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use here is Tier C investigational.
- What evidence exists?
- Tier C (investigational). No clinical study of leech therapy for ulcerative proctitis was identified. Evidence-based first-line management of ulcerative proctitis is topical mesalamine (suppositories or enemas) for induction and maintenance, topical corticosteroids for refractory cases, oral mesalamine added if topical therapy is incomplete, and for treatment-refractory disease oral or topical immunomodulators and biologic therapy.
- Main risks
- Bleeding from each bite site for 6 to 10 hours after the leech detaches
- Iron-deficiency anemia from cumulative blood loss across multiple sessions
- Aeromonas hydrophila wound infection from leech gut bacteria (uncommon outside reconstructive surgery, but possible)
- Allergic reaction to leech saliva (rare; ranges from local itching to anaphylaxis)
- Small Y-shaped bite marks or skin colour changes at the bite sites, which usually fade over weeks to months
- Local pain, bruising, swelling, or itching for 1 to 3 days after each session
- Local bleeding into already inflamed and friable rectal tissue
- Risk of seeding infection in an ulcerated mucosa (leeches must NOT be placed on rectal mucosa)
- Who should not consider this
- Patients with active severe flare with fever, tachycardia, or systemic symptoms (need urgent IBD care)
- Patients who have not had a proper trial of topical mesalamine for at least 4-6 weeks
- Patients with C. difficile or other infectious colitis (treat the infection first)
- Anyone on blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran or heparin (daily aspirin alone is not a contraindication: tell your doctor, who starts with fewer leeches)
- People with hemophilia or any other inherited bleeding disorder
- Patients with anemia
- People with an active infection at the planned application site
- What to ask your clinician
- Has my proctitis been confirmed by colonoscopy and biopsy as ulcerative (not Crohn or infectious)?
- Have I tried topical mesalamine, topical steroids, and oral mesalamine?
- Have biologic options been discussed if standard therapy has failed?
- What is the published evidence base for leeches in IBD?
- What is the bleeding-risk plan given inflamed mucosa?
- How will worsening of inflammation be detected and managed?
- When to seek urgent care
- Bleeding from a bite site that soaks through more than one dressing per hour
- Bleeding that continues more than 24 hours after the leech detached
- Spreading redness, warmth, swelling, pus, or red streaks around any bite site
- Fever over 38.0 C / 100.4 F, chills, or feeling suddenly unwell after a session
- Hives, facial or tongue swelling, throat tightness, or any difficulty breathing
- Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
- Heavy rectal bleeding, especially with weakness or lightheadedness
- High fever, severe abdominal pain, or signs of bowel perforation
- Inability to pass stool with progressive abdominal distention (possible toxic megacolon)
What this does NOT mean
- It does not mean leech therapy is FDA-cleared for ulcerative proctitis — the only FDA clearance is venous congestion in microsurgical reconstruction (K040187, June 2004).
- It does not replace topical mesalamine, topical steroids, or biologic therapy.
- It does not change the underlying inflammatory bowel disease.
- It does not lower the long-term colorectal cancer risk that comes with chronic IBD.
- It does not have controlled-trial evidence in IBD; no clinical study of leech therapy in ulcerative colitis or proctitis was identified.
Safety cross-references
Clinical Profile
- Category
- Gastrointestinal
- ICD-10
- K51.20, K51.211, K51.219
- Safety tier
- High
Evidence Summary
Ulcerative proctitis (ulcerative colitis limited to the rectum) is managed per ACG and AGA guidelines with topical 5-aminosalicylates (mesalamine suppositories or enemas) as first-line therapy, topical corticosteroids for refractory cases, and oral 5-ASA or biologics for extension or escalation. No clinical study of leech therapy for ulcerative proctitis or ulcerative colitis was identified in PubMed, Europe PMC, Crossref, ClinicalTrials.gov or the Baskova and Isakhanyan (2004) monograph; the only reports of leech therapy found are two single-patient adverse-event reports (pyoderma gangrenosum after leech therapy in a patient with ulcerative colitis, Sadeghi 2016; an anal abscess after leech therapy for hemorrhoids, Mentes 2019). Its use is investigational and any rationale is mechanistic only, and the autoimmune pathophysiology of ulcerative colitis is not directly addressed by leech salivary pharmacology. Direct mucosal (intrarectal or perianal) application is contraindicated. Evidence is grade D.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)
Contraindications
- Hemophilia or another bleeding disorder
- Taking anticoagulants (blood thinners such as warfarin or heparin)
- Anemia or suppressed blood formation
- Low blood pressure, shock, collapse or fainting
- Severe wasting (cachexia)
- Intolerance of leeches or a history of severe allergic reactions
- Pregnancy
- Stomach or duodenal ulcer, erosive gastritis
- Acute infectious disease or high fever
- Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
- Drinking alcohol at the time of treatment
- No consent from the patient
- Severe acute flare with systemic toxicity
- Toxic megacolon
- Cytomegalovirus or C. difficile superinfection
- Active perianal disease (consider Crohn's)
- Any perianal or intrarectal placement
Related Conditions
Hemorrhoids (Grade II-III, Symptomatic)
Investigational use for symptomatic relief of grade II-III internal/external hemorrhoidal disease; does not address anatomic prolapse.
Chronic Anal Fissure (>8 Weeks)
Investigational idea for chronic anal fissure refractory to medical therapy; no clinical study identified; sphincterotomy remains the gold standard.
Non-Alcoholic Fatty Liver Disease (Investigational Adjunct)
Investigational adjunct in NAFLD/MASLD; no human clinical study identified; weight loss, dietary modification, and resmetirom remain primary.
Hepatic Portal Congestion (Non-Cirrhotic, Investigational)
Highly investigational adjunct for non-cirrhotic hepatic congestion; uncontrolled Russian series only; cirrhosis and portal hypertension are absolute exclusions.